Johnson & Johnson (JNJ) Q1 2026 (USD) : EPS 2.70 (exp. 2.68), Revenue 24.1bln (exp. 23.61bln), Net Income 6.61bln (exp. 6.55bln), Current FY Rev. 100.3-101.3bln (prev. 100-101bln; exp. 100.62bln), quarterly dividend +3.1% to 1.34/shr (prev. 1.30/shr)
- Growth was driven primarily by DARZALEX (GMAB DC), CARVYKTI, ERLEADA, and RYBREVANT/LAZCLUZE in Oncology.
- Innovative Medicine worldwide operational sales grew 7.4%*, with net acquisitions and divestitures positively impacting growth by 1.8% primarily due to CAPLYTA.
Context
Johnson & Johnson's Q1 2026 results beat expectations on both earnings and revenue, demonstrating solid performance driven by its Oncology portfolio. The upward revision of their full-year revenue guidance signals confidence in sustained growth, while the increased dividend reflects a commitment to returning value to shareholders, enhancing the attractiveness of the stock amidst industry challenges.
Trade the TapeGet this analysis live, the moment it breaksNewsquawk's real-time dashboard delivers market-moving headlines and instant context to your desk before the rest of the market reacts.
Open Dashboard#UNITED STATES#USD#EUR#JAPAN#JPY#UNITED KINGDOM#GBP#EUROPE#JOHNSON & JOHNSON#JNJ.US#IMPORTANT#FOREX#EQUITIES#METALS#EU SESSION#PHARMACEUTICALS#METALS & MINING#PHARMACEUTICALS (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#JNJ#DXY#US EQUITIES